ABSTRACT 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages dopaminergic neurons as seen in Parkinson's disease. Although increasing evidence suggests an involvement of glia in MPTP neurotoxicity, the nature of this involvement remains unclear. Exploiting the advantage of cell culture systems, we demonstrated that microglia, but not astroglia, significantly enhanced the progression of MPTP-induced dopaminergic neurodegeneration. Characterization of the temporal relationship between neurodegeneration and microglial activation demonstrates that reactive microgliosis resulting from MPTP-initiated neuronal injury, but not direct activation, underlies the microglia-enhanced MPTP neurotoxicity. Mechanistically, through the release of NADPH oxidase-derived reactive oxygen species, microglia contribute to the progressive neuronal damage. Among the factors measured, the production of extracellular superoxide was the most prominent. NADPH oxidase inhibitor, apocynin, attenuated MPTP-induced dopaminergic neurodegeneration only in the presence of glia. More importantly, dopaminergic neurons from mice lacking NADPH oxidase, a key enzyme for superoxide production in immune cells, are significantly more resistant to MPTP neurotoxicity than those from wild-type controls, and microglia dictate the resistance. This study demonstrates that reactive microgliosis triggered by MPTP-induced neuronal injury and NADPH oxidase-mediated superoxide production in microglia constitute an integral component of MPTP neurotoxicity. This study also suggests that NADPH oxidase may be a promising target for therapeutic interventions in Parkinson's disease.
arkinson's disease (PD) is a common neurodegenerative disorder, and there are no effective therapeutic drugs to halt progression of the disease (1, 2) . The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) PD model has been widely used to study pathogenesis and to test neuroprotective strategies. MPTP is converted into 1-methyl-4-phenylpyridinium (MPP + ) by monoamine oxidase B (MAO-B) in astroglia. MPP + is then taken up by the dopamine transporter (DAT) and concentrated in dopamine neurons where it inhibits complex I of the mitochondrial electron transport chain, resulting in ATP depletion, increased free radical production, and subsequent cell death (3, 4) .
P
Increasing evidence suggests a role for glial activation in the pathogenesis of PD (5) (6) (7) . Recently, we have reported that the inflammatory process induced by the inflammogen lipopolysaccharide (LPS) resulted in a progressive and selective dopaminergic neurodegeneration, which was associated with increased microglia-derived reactive oxygen species (ROS) production (8) . We have also demonstrated that dopaminergic neurodegeneration induced by the pesticide rotenone could not be due solely to the impairment of the neuronal mitochondrial complex I activity, but also involved the participation of the resident immune cells of the brain, the microglia. Microglial NADPH oxidase-mediated production of ROS played a dominant role in microgliaenhanced rotenone neurotoxicity (9) . Recent reports from other labs suggest an important role of glial activation in MPTP neurotoxicity. Administration of MPTP to mice caused a robust gliosis accompanied by an up-regulation of inducible nitric oxide synthase (iNOS) in the substantia nigra (SN); iNOS-deficient mice are more resistant to MPTP toxicity than their wild-type littermates (10, 11) . The observations that cyclooxygenase (COX)-2-deficient mice are resistant to MPTP and that COX inhibitors suppressed MPTP neurotoxicity (12, 13) suggest the involvement of COX-2 and inflammatory prostaglandins in MPTP-induced neurotoxicity. Blockade of microglial activation with minocycline, a semisynthetic second-generation tetracycline, prevents nigrostriatal dopaminergic neurodegeneration induced by MPTP (14, 15) . These findings, coupled with the demonstration of increased iNOS expression and elevated proinflammatory cytokines in the SN of patients with PD but not from age-matched control subjects (16) (17) (18) suggest that glial activation may contribute to the neurodegenerative process of PD. However, several important questions remain unanswered: a) Which type of glia mediates the glia-enhanced MPTP neurotoxicity? b) Is glial activation a direct effect of MPTP/MPP + or an indirect effect due to MPTP-induced neuronal damage? c) What are the major factors released by activated glia that mediate the glia-enhanced dopaminergic neurodegeneration in the MPTP model and in PD?
In this study, using cell culture systems, we demonstrated that microglia, but not astroglia, significantly elevated MPTP/MPP + neurotoxicity. Analysis of the temporal relationship between dopaminergic neurodegeneration and microglial activation revealed that neurodegeneration preceded microglial activation. Further studies on the underlying mechanism of microgliaenhanced MPTP neurotoxicity indicated that microglial NADPH oxidase-derived ROS and nitric oxide (NO) played an important role.
MATERIALS AND METHODS

Materials
Cell culture ingredients were obtained from Invitrogen (San Diego, CA). [ 3 H]Dopamine (DA; 30 Ci/mmol) and [ 3 H]GABA (90 Ci/mmol) were from NEN (Boston, MA). The polyclonal antiglial fibrillary acidic protein (GFAP) antiserum and antibody diluent were from DAKO (Carpinteria, CA). The polyclonal anti-tyrosine hydroxylase (TH) antiserum was a gift from GlaxoSmithKline (Research Triangle Park, NC). The monoclonal anti-neuron-specific nuclear protein (Neu-N) antibody was from Chemicon (Temecula, CA). The antibody against the F4/80 antigen was from Serotec (Raleigh, NC). The Vectastain ABC kit and biotinylated secondary antibodies were from Vector Laboratories (Burlingame, CA). Apocynin was from Fluka (Milwaukee, WI). All other reagents were from Sigma.
Mesencephalic neuron-glia cultures
Primary ventral mesencephalic neuron-glia cultures were prepared from the brains of embryonic day 12/13 gp91 phox -deficient (PHOX −/− ) or wild-type (PHOX +/+ ) C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) following our published protocol (9) with modifications. Cells were seeded to poly-D-lysine-coated (20 µg/ml) 24-well (6×10 5 /well) or 96-well (1.2×10 5 /well) plates and maintained in 0.5 ml/well (24-well) or 0.1 ml/well (96-well) of minimum essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 10% heat-inactivated horse serum (HS), 1 g/l glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 µM nonessential amino acids, 50 U/ml penicillin, and 50 µg/ml streptomycin. For treatment, the cultures were maintained in 1.0 ml/well (24-well plate) or 0.2 ml/well (96-well plate) of treatment medium (MEM containing 2% FBS, 2% HS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 U/ml penicillin, and 50 µg/ml streptomycin). Seven-day-old cultures were used for treatment. At the time of treatment, the cultures were made up of ~13% F4/80-immunoreactive (IR) microglia, 48% GFAP-IR astrocytes, and 39% Neu-N-IR neurons of which 2.5-3.5% were TH-IR neurons.
Mesencephalic neuron-enriched cultures
Primary ventral mesencephalic neuron-enriched cultures were prepared by following our published protocol (9) with modifications. Dissociated mouse ventral mesencephalic cells were first seeded at 6×10 5 cells/well as described above. Two days after initial seeding, cytosine β-Darabinofuranoside (ara-C, 5-8 µM) was added to suppress the proliferation of glial cells (9, 19) . Seven days after plating, the cultures were treated with vehicle or MPTP/MPP + in treatment medium containing 2 µM ara-C. Immunocytochemical analysis indicated that, at the time of treatment, the cultures contained <0.1% F4/80-IR microglia and 8% GFAP-IR astrocytes. Of the Neu-N-IR neurons, 2.7-3.4% were TH-IR neurons. The number of TH-IR neurons in neuronenriched cultures did not differ from that in neuron-glia cultures. In addition, there was no significant difference between PHOX −/− and PHOX +/+ mice in cell composition, either in neuronglia cultures or in neuron-enriched cultures.
Microglia-enriched cultures
Microglia were prepared from whole brains of 1-day-old mice, as described previously (9, 20) . The enriched microglia were >95% pure, as determined by F4/80-and GFAP-IR.
Neuron-astroglia cocultures
Primary neuron-astroglia cocultures were prepared from C57BL/6J mice by coculturing fetal midbrain neurons with a confluent monolayer of astroglia. Briefly, after six consecutive passages, nearly pure astroglia were seeded to 24-well plates (1×10 5 /well). Upon reaching confluence, fetal midbrain cells from E12/13 mice were added and maintained in 0.5 ml/well midbrain culture medium. To suppress glial proliferation, we added ara-C (10 µM) 2 days later. Seven-day-old cocultures were used for treatment and neurotoxicity was assessed 7 days after treatment.
Immunocytochemistry
Immunostaining was performed as previously described (9, 21) with the following primary antibodies: anti-Neu-N (1:2000), anti-GFAP (1:1000), anti-TH (1:20000), and anti-F4/80 antigen (1:20) . Briefly, after blocking, formaldehyde-fixed cells were incubated overnight at 4°C with primary antibodies diluted in antibody diluent. The bound primary antibody was visualized by incubation with an appropriate biotinylated secondary antibody, followed by the Vectastain ABC reagents and color development with 3,3′-diaminobenzidine. Images were recorded with a CCD camera and the MetaMorph software. For visual enumeration of the immunostained cells, nine representative areas per well were counted. For each condition, two to four wells were used for cell counting. Counting was always performed by two to three individuals in a blind manner.
Uptake assay
Uptake of [
3 H]DA or [ 3 H]GABA was performed as previously described (9) . Nonspecific uptake for DA and GABA was determined in the presence of 10 µM mazindol and 10 µM NO-711, respectively.
Superoxide assay
The production of superoxide was determined by measuring the superoxide dismutase (SOD)-inhibitable reduction of cytochrome c as previously described (8), with modifications. Sevenday-old mesencephalic neuron-glia cultures grown in 96-well plates were treated with MPTP, MPP + , or vehicle in 150 µl of phenol red-free treatment medium. At 0, 24, or 96 h after treatment, 50 µl of ferricytochrome c (160 µM) in treatment medium with and without 800 U/ml SOD was added. The cultures were incubated for 15 min at 37°C. Afterward, the absorbance at 550 nm was read with a SpectraMax Plus microplate spectrophotometer (Molecular Devices, Sunnyvale, CA).
Nitrite and tumor necrosis factor (TNF)-α assays
The production of NO and TNF-α was determined using Griess reagent and a mouse TNF-α enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN), respectively, as previously described (9) .
Statistical analysis
All values are expressed as the mean ± SE. Statistical significance was assessed by ANOVA, followed by the Bonferroni's t test, using the StatView program. In all analyses, the null hypothesis was rejected at the 0.05 levels.
RESULTS
Glia increase MPP + -induced dopaminergic neurodegeneration
To investigate the role of glia in dopaminergic neurodegeneration in PD, we treated primary neuron-glia or neuron-enriched cultures with MPP + for 7 days and assessed the neurotoxicity using several parameters. Because DAT is known to be sensitive to inhibition by ROS (22) (23) (24) (Fig. 1A, B) . Aside from the reduction in cell numbers, TH-IR neurons in the MPP + -treated cultures displayed shorter and less elaborate neurites compared with those in control cultures (Fig. 1C) . The difference in MPP + neurotoxicity between neuron-glia and neuron-enriched cultures indicates that glia play an important role in the MPP + neurotoxic process.
Microglia, but not astroglia, render dopaminergic neurons more sensitive to MPP + neurotoxicity
To determine the type of glia mediating the glia-enhanced MPTP neurotoxicity, we analyzed the effect of addition of microglia or astroglia to neuron-enriched cultures on the MPP + neurotoxicity. At low concentrations of MPP + (<1.0 µM), the addition of microglia significantly increased the MPP + neurotoxicity ( Fig. 2A) . Treatment of neuron-enriched cultures with 0.1 µM MPP + resulted in a 4% reduction in [ 3 H]DA uptake, whereas the addition of microglia (7.5×10 4 /well) to neuron-enriched cultures, a level comparable to that observed in the neuronglia cultures, caused a 33% reduction in [ 3 H]DA uptake ( Fig. 2A) , close to the degree of reduction observed in neuron-glia cultures treated with the same concentration of MPP + (Fig.  1A) . At a higher concentration of MPP + (1.0 µM), the neurotoxicity was the same with and without the addition of microglia. Furthermore, the increase in the MPP + neurotoxicity positively correlated with the number of microglia added to the neuron-enriched cultures (Fig. 2B ). In contrast, the addition of astroglia (7.5×10 4 /well) to neuron-enriched cultures did not significantly affect the sensitivity of dopaminergic neurons to MPP + toxicity (Fig. 2C) ; the addition of more astroglia (>15×10 4 /well), close to the composition of astroglia in neuron-glia cultures, significantly decreased the basal [ 3 H]DA uptake but did not affect the sensitivity (data not shown). To confirm the inefficiency of astroglia in elevation of MPP + neurotoxicity, we also treated neuron-astroglia cocultures with MPP + and found that the presence of astroglia failed to affect the MPP + neurotoxicity (Fig. 2D ). These results demonstrate that microglia, but not astroglia, play a pivotal role in the enhancement of MPP + -induced neurodegeneration. (Fig. 3) . Taken together, these data indicate that the presence of microglia did not affect the selectivity of MPTP/MPP + neurotoxicity, consistent with the in vivo observation that MPTP selectively killed dopaminergic neurons.
MPTP/MPP + produces reactive microgliosis but not direct microglial activation
To examine the temporal relationship between neurodegeneration and microglial activation, we treated neuron-glia cultures with 0.5 µM MPTP or MPP + and then examined the time course of dopaminergic neurodegeneration and microglial activation. The degeneration of dopaminergic neurons was detected as early as 1 day after MPTP/MPP + treatment (Fig. 4A) , whereas the activation of microglia was undetectable at this time point (Fig. 4B, C) , indicating that MPTPinduced neurodegeneration preceded microglial activation. Twenty-four hours after treatment with vehicle or 0.5 µM MPTP/MPP + , only a few small and faintly F4/80-IR microglia were observed. Two days after the treatment, the reduction in [ 3 H]DA uptake became more evident (Fig. 4A) , and the F4/80-IR microglia exhibited the characteristics of activated microglia (data not shown). More strikingly, the number of F4/80-IR microglia increased significantly (Fig. 4B) . Prolonged treatment (4-7 days) resulted in more prominent activation of microglia, as shown by morphological changes (increased cell size, staining intensity for F4/80, and shape changes) and an increasing elevation in the number of F4/80-IR microglia (Fig. 4B, C) . In comparison, LPS, which is known to cause neuronal damage by direct activation of microglia (25) , induced dramatic microglial activation as early as 12 h after treatment, whereas neurodegeneration was undetectable at this time point.
We next examined the major factors mediating the enhanced MPTP toxicity. Among the factors we measured, the production of superoxide was the most prominent. Time-and concentrationdependence studies revealed that, in contrast to the immediate release induced by LPS that we documented in our previous report (8) , MPTP/MPP + -induced superoxide production was observed only after the occurrence of substantial neuronal damage, as shown by a 217% and 350% increase in superoxide production after treatment with 0.5 µM MPTP and MPP + for 4 days, respectively (Fig. 5A) . Analysis of the levels of nitrite, an indicator of NO production, in supernatants from neuron-glia cultures treated with MPTP/MPP + showed similar changes. Treatment with MPP + (0.25 and 0.5 µM) for 4 days increased the levels of nitrite to 2.1±0.3 µM and 2.5±0.1 µM, respectively; the levels of nitrite in the cultures treated with 0.5 and 1.0 µM MPTP were 0.9±0.15 and 1.1±0.21 µM, respectively (n=3 for all assays). The quantity of nitrite in either vehicle-or MPTP/MPP + -treated cultures for 24 or 48 h was below the detection limit (0.5 µM). In contrast to the changes in superoxide and nitrite levels, there was no detectable production of TNF-α (detection limit: 5 pg/ml) in vehicle-or MPTP/MPP + -treated cultures throughout the time period examined (data not shown).
The finding that the activation of microglia was not evident in the absence of significant neuronal injury prompted us to speculate that the microglial activation was not a direct effect of either MPTP or MPP + , but a reactive response to neuronal damage. To test this hypothesis directly, we first examined the effect of pargyline on MPTP-induced neurodegeneration.
Pargyline is a mixed MAO-A and MAO-B inhibitor, which blocks the conversion of MPTP to MPP + . Simultaneous administration of MPTP and pargyline blocked the damage to dopaminergic neurons, as shown by a 59% and 7% reduction in [ 3 H]DA uptake in neuron-glia cultures treated with MPTP (0.5 µM) alone or MPTP combined with pargyline (10 µM). Associated with the blockade of MPTP-induced dopaminergic neurodegeneration, in the neuronglia cultures pretreated with pargyline, microglia were not activated. These data indicate that MPTP cannot directly activate microglia in the absence of neuronal damage. Next, we directly stimulated mouse microglia, mixed glia and BV2 microglial cell line with MPTP/MPP + , at concentrations ranging from 0.1-50 µM, to measure the production of superoxide, NO, and TNF-α in the culture media. The quantities of all these factors were at or below the detection limits for the assays. Hence, these results demonstrate that the microglia-enhanced neurotoxicity is due to reactive microgliosis.
Microglial NADPH oxidase-derived ROS play an important role in MPTP/MPP + neurotoxicity
Because extracellular superoxide is an important factor mediating the MPTP/MPP + toxic process and NADPH oxidase, also called phagocyte oxidase (PHOX), is an enzyme that appears to be a major source of extracellular superoxide production in microglia, we speculated that microglial NADPH oxidase played an important role in microglia-enhanced MPTP/MPP + neurotoxicity. Three lines of evidence support this hypothesis. First, treatment of neuron-glia cultures from PHOX +/+ mice with MPTP/MPP + (0.5 µM) for 4 days caused significant superoxide production (Fig. 5A) . Second, in the cultures from PHOX +/+ mice, the NADPH oxidase inhibitor apocynin attenuated MPTP/MPP + neurotoxicity only in the presence of glia. Unlike PHOX +/+ mice, in the cultures from PHOX −/− mice, apocynin did not exert any protective effect against MPTP/MPP + neurotoxicity even in the presence of glia. Third, more importantly, in neuron-glia cultures, dopaminergic neurons from PHOX −/− mice were more resistant to MPTP/MPP + neurotoxicity than those from PHOX +/+ mice (Fig. 6) . At low concentrations of MPTP or MPP + , the difference was much more evident, similar to the pattern of differential sensitivity of dopaminergic neurons in neuron-glia and neuron-enriched cultures (Fig. 1 ).
Given the difference in MPTP/MPP + -induced neurodegeneration between PHOX
−/− and PHOX +/+ mice in neuron-glia cultures, further analysis showed that microglia, but not other cell types, were responsible for the difference (Table 1 ). In the neuron-enriched culture system, there was no difference in MPP + neurotoxicity between PHOX −/− mice and PHOX +/+ mice. MPP + neurotoxicity in neuron-enriched cultures from both types of mice was equally increased by the addition of microglia from PHOX +/+ mice. We observed the same phenomenon after the addition of microglia from PHOX −/− mice. Moreover, the addition of microglia from PHOX +/+ mice was more effective than those from PHOX −/− mice in enhancing MPP + neurotoxicity, suggesting the involvement of other factors derived from microglia (Table 1) . These results, coupled with the observation that in cultures from PHOX +/+ mice apocynin did not significantly attenuate MPP + neurotoxicity in the absence of glia but did so effectively in the presence of glia (Fig. 5C ), indicate that microglial NADPH oxidase-derived superoxide plays an important role in MPTP/MPP + neurotoxicity, and other factors such as NO may also be involved in the neurotoxic process.
DISCUSSION
Recent reports indicate that glia participate in MPTP-induced dopaminergic neurodegeneration in the rodent PD model (10, 11, 14, 15, 26) . But the nature of the glial involvement remains unknown, due to the rapid neuronal death and glial activation after dosing the animals with MPTP. In this study, we used primary cell cultures prepared from the mesencephalon as an in vitro PD model. We found that microglia, but not astroglia, significantly elevated the MPP + -induced dopaminergic neurodegeneration (Fig. 1, 2 ) and the presence of microglia did not affect the selectivity of MPTP/MPP + neurotoxicity (Fig. 3) . Time course studies revealed that unlike LPS (8) or rotenone (9) , MPTP failed to directly activate microglia; the activation of microglia was a consequence of neuronal damage (Fig. 4) . Free radicals such as superoxide or NO released by reactive microglia are the major players responsible for the enhanced toxicity of MPTP.
Microglia play a role of immune surveillance under physiological conditions and become activated in response to neuronal injuries and immunological challenges (27, 28) . Although microglial activation sometimes may be associated with beneficial effects, more commonly, activated microglia exert deleterious effects through the release of a variety of noxious factors or direct phagocytosis (5, (29) (30) (31) (32) . We and others have previously demonstrated that direct injection or infusion of LPS into the rat SN caused a dramatic microglial response leading to significant dopaminergic neurodegeneration (8, (33) (34) (35) , indicating that microglial activation is capable of initiating neurodegeneration. The question asked here was how MPTP activates microglia: direct activation by MPTP/MPP + or reactive gliosis as a result of MPP + -induced neuronal injury? The term "reactive gliosis" is used to describe the response of endogenous glial cells to neuronal damage (36) . In the present study, we excluded the possibility that either MPTP or MPP + directly activates microglia. This conclusion is based on the following observations. First, the activation of microglia was not evident in the absence of neuronal injury after MPTP/MPP + treatment (Fig.  4) . Second, microglia-derived factors were detected only after the occurrence of substantial neuronal damage. Third, consistent with other reports (37) (38) (39) , pargyline completely blocked the damage of dopaminergic neurons induced by MPTP. More importantly, associated with the attenuation of MPTP neurotoxicity, pargyline abolished the microglial activation (this study). Fourth, primary glial cultures and BV2 microglial cell line did not produce superoxide, NO, or TNF-α after direct stimulation with MPTP/MPP + . These results demonstrate that the microgliaenhanced neurotoxicity is due to reactive microgliosis and suggest the possibility that similar phenomena may occur in the MPTP-mouse model or even in PD patients. Furthermore, enhanced neurodegeneration following microglial activation is unlikely restricted in the MPTP model. Reactive gliosis induced by other toxins, such as 6-OHDA, dopamine, kainic acid, and teratogen cyclophosphamide, also plays an important role in neurodegenerative process. For example, a recent study has demonstrated that neuronal damage induced by cyclophosphamide is capable of inducing reactive microgliosis, which, in turn, releases various cytokines such as TNF-α, interleukin-1, interleukin-6, transforming growth factor-β, macrophage colonystimulating factor, and nitric oxide. By releasing these neurotoxic factors, reactive microgliosis also become a cause of further neuronal damage (40) .
We also addressed the role of astroglia in glia-enhanced MPTP toxicity (Fig. 2C, 2D ). Because the neurotoxicity of MPTP is dependent on the formation of MPP + in astroglia, astroglia are indispensable for MPTP neurotoxicity. However, in this study, we tried to dissect the role of either microglial activation or astroglial activation, as a part of neuroinflammation, in the MPTPinduced neurotoxicity. Consistent with the notion that astroglial reaction is secondary to the loss of dopaminergic neurons (10, 15, 31, 41, 42) , we also found reactive gliosis of astroglia after MPTP/MPP + treatment (data not shown). Moreover, we found that the presence of astroglia did not increase MPP + neurotoxicity (Fig. 2C, 2D ). Taken together, our data indicate that microglia, but not astroglia, play a pivotal role in glia-enhanced MPTP neurotoxicity.
Further investigation of the underlying mechanism of microglia-enhanced neurotoxicity induced by MPTP demonstrated that microglial NADPH oxidase-derived superoxide is a major factor. Several lines of evidence demonstrated this conclusion. First, among the factors we measured, extracellular superoxide production was the most prominent. Superoxide is a poorly reactive radical that in and of itself is not very toxic. Furthermore, superoxide cannot directly transverse cellular membranes (43) , making it unlikely that microglia-derived extracellular superoxide would enter dopaminergic neurons and directly trigger toxic intraneuron events. Alternatively, superoxide may exert its toxicity by either converting to hydrogen peroxide or reacting with NO in the extracellular space to form the highly reactive tissue-damaging species, peroxynitrite. Hydrogen peroxide and peroxynitrite can cross the cell membrane and cause direct injury to dopaminergic neurons (44) (45) (46) . Second, significant superoxide production was induced by MPTP/MPP + in neuron-glia cultures from PHOX +/+ mice but not from PHOX −/− mice (Fig. 5B) .
Third, the NADPH oxidase inhibitor, apocynin, significantly attenuated MPTP/MPP + neurotoxicity only in neuron-glia cultures from PHOX +/+ mice but not from PHOX −/− mice (Fig.   5C ). Fourth, and most importantly, dopaminergic neurons of PHOX −/− mice were more resistant to MPTP/MPP + than those of PHOX +/+ mice, and microglia determined this difference (Fig. 5C , Table 1 ). The resistance of dopaminergic neurons of PHOX −/− mice in neuron-glia cultures to MPTP/MPP + neurotoxicity most likely resulted from the absence of extracellular superoxide production (Fig. 5B) .
NADPH oxidase is a superoxide-producing enzyme, mainly expressed in phagocytic cells. In response to stimuli, the cytosolic complex, composed of p47 PHOX , p67 PHOX , and p40 PHOX , translocates to the membrane and associates with membrane components (gp91 PHOX and p22 PHOX ) to assemble the functional oxidase (47, 48) . Increasing evidence suggests that various subunits of NADPH oxidase are also expressed in nonphagocytic cells such as sympathetic ganglion neurons and cortical neurons (49) (50) (51) , which suggests the possibility that neurons in general may express NADPH oxidase. However, our results indicated that microglia, but not neurons, dictated the differential sensitivity of dopaminergic neurons to MPTP/MPP + neurotoxicity. This conclusion is based on the following observations. First, unlike neuron-glia cultures (Fig. 6) , in neuron-enriched cultures there is no difference in MPP + neurotoxicity between PHOX −/− mice and their wild-type littermates (Table 1) . Second, the MPP + -induced neurodegeneration in neuron-enriched cultures from both types of mice was equally increased by the addition of microglia (Table 1) . Third, apocynin could not prevent MPP + neurotoxicity in the absence of glia, but did so effectively in the presence of glia. Dopaminergic neurons are known to be particularly vulnerable to oxidative damage due to their intrinsic characteristics such as a high content of oxidation-prone dopamine and lipids, an increased accumulation of iron that may participate in the formation of ROS, and a reduced antioxidant capacity (52, 53) . In addition, it has been proposed that extracellular ROS appear to promote the mitochondria-mediated generation of intracellular ROS (54) . Therefore, the combination of the intrinsic vulnerability of dopaminergic neurons and increased oxidative burden driven by intracellular ROS, due to MPP + -induced mitochondrial complex I inhibition and, extracellular ROS, released from activated microglia, underlies the microglia-enhanced MPTP neurotoxicity.
NO was another factor associated with microglia-enhanced MPTP neurotoxicity. NO, a weak oxidant, by contributing to peroxynitrite formation, plays an important role in the MPTP mouse model and possibly in PD itself. The elevated NO production in the neuron-glia cultures after MPTP treatment and the less efficiency of microglia from PHOX −/− mice than those from PHOX +/+ mice in increasing MPP + toxicity supported this notion. Furthermore, the demonstration that ablation of iNOS or nNOS attenuates the dopaminergic neuronal loss induced by MPTP (10, 11, 14, 15, 44, 55) gives support to this notion.
Although we have not measured the levels of intracellular MPP + and extracellular MPTP, we postulate that the mutation of NADPH oxidase was not associated with alterations in the formation of MPP + , because we also observed a differential MPP + neurotoxicity between PHOX −/− and PHOX +/+ mice (Fig. 6B, 6C ), whose pattern was similar to that induced by MPTP (Fig. 6A, 6C ). Note that at high concentrations of MPP + , the difference in MPP + neurotoxicity was not evident in the presence or absence of microglia; similarly, in neuron-glia cultures from PHOX −/− or PHOX +/+ mice, this difference also diminished. This lack of difference was likely attributable to MPP + direct neurotoxicity solely as a consequence of the inhibition of mitochondrial function and ATP depletion.
In addition, the observed difference in the time course of microglial activation in vitro (this study) and in vivo (10) could be due to that we used low concentrations of MPTP/MPP + and that the density of dopaminergic neurons in our culture system was much lower than that in SN. Hence dopaminergic neuronal injury in our in vitro study was much milder than that observed in vivo. This has provided us with an opportunity to explore the temporal relationship between neurodegeneration and microglial activation. MPTP/MPP + neurotoxicity was detected as early as 1 day, whereas no apparent microglial activation was observed. As treatment time progressed, dopaminergic neurodegeneration became more and more evident, which was associated with increasing microglial activation, indicating that MPTP/MPP + -induced neurotoxicity proceeded microglial activation.
Our findings provide evidence for an important role for microglial NADPH oxidase-derived ROS in the vicious cycle of neurodegeneration and reactive microgliosis in the MPTP model and in PD. Therefore, NADPH oxidase may be a valuable target for the development of novel therapeutic agents aimed at retarding the progression of PD. Furthermore, consistent with the literature, we find that in addition to NADPH oxidase-derived ROS, NO is another major factor in the MPTP toxic process. Hence, multidrug approaches similar to those taken in cancer and AIDS therapies may represent the most promising therapeutic strategies. 
